Drug Trial Radar · NCT05089708
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Last checked: Nov 20, 2026Latest source record: Dec 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Dec 22, 2021
Primary completion
Dec 15, 2022
Study completion Dec 15, 2022
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Oct 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants
Conditions
- Acne Vulgaris
Interventions
Trifarotene CreamDrug
Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
Trifarotene Vehicle CreamDrug
Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24Time frame: Baseline and Week 24
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Galderma Investigational Site #8636
Fountain Valley, California
Galderma Investigational Site #8224
Fremont, California
Galderma Investigational Site #8358
San Diego, California
Galderma Investigational Site #9955
San Diego, California
Galderma Investigational Site #7012
Lutz, Florida
Galderma Investigational Site #8184
Maitland, Florida
Galderma Investigational Site #8764
Tampa, Florida
Galderma Investigational Site #9950
Evansville, Indiana
Galderma Investigational Site #9952
Baton Rouge, Louisiana
Galderma Investigational Site #8606
New Orleans, Louisiana
Galderma Investigational Site #8012
Glenn Dale, Maryland
Galderma Investigational Site #9948
Hyattsville, Maryland
Galderma Investigational Site #8554
Detroit, Michigan
Galderma Investigational Site #8108
Las Vegas, Nevada
Galderma Investigational Site #8620
New York, New York
Galderma Investigational Site #9956
New York, New York
Galderma Investigational Site #9949
New York, New York
Galderma Investigational Site #9953
Tulsa, Oklahoma
Galderma Investigational Site #8207
Nashville, Tennessee
Galderma Investigational Site #9920
Arlington, Texas
Galderma Investigational Site #8329
San Antonio, Texas
Galderma Investigational Site #8433
San Antonio, Texas
Galderma Investigational Site #6277
Pontevedra, Spain
Galderma Investigational Site #6192
Zaragoza, Aragon, Spain
Galderma Investigational Site #6278
Manises, Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.